|
Learn More About Deep and Draining
We recommend the following reference(s):
Shop for Deep and Draining Products
Click here to learn more about other topics.
Keywords: SilvaSorb®
Targeted antimicrobial protection
SilvaSorb® provides targeted antimicrobial
protection for every type of wound.
Helps manage bacterial burden1,2,8
Effective against a broad spectrum
of bacteria and fungi.
Constant powerful antimicrobial
protection1,2
Controlled-release antimicrobial silver.
Advanced fluid management 1
SilvaSorb Sheet and Cavity absorb
at least five times their weight in
exudate or donate moisture
as needed.
Extended wear time3,4,5
Effective for up to seven days.
Three days for the gel.
Optimal moisture levels
Balanced moisture management
helps create an ideal healing
environment.Will not macerate
or dry wounds.
Easy to use for antimicrobial
efficacy
No need to pre-wet or re-wet.
Can be cut to size.
Gentle for patient 6,7
Non-adherent and no residue left
in wounds. Reduced pain compared
to silver sulfadiazine ointment in
burn treatment.
Simple wound monitoring
Transparent.Will not stain wound
or surrounding skin.
Cost-Effective5
Reduces change frequency and
staff time.
The SilvaSorb® family combines targeted, ionic silver antimicrobial
protection with advanced fluid management. Utilizing our
Microlattice® technology, SilvaSorb controls the release of silver at
amounts that are ideal for killing bacteria and fungi, without harming
healthy tissue.
SilvaSorb — for flat wounds with dry to heavy exudate.
Use SilvaSorb sheets and perforated sheets for a seven-day
antimicrobial barrier and the ability to donate or absorb moisture.
SilvaSorb Cavity — for tunneling,undermined or heavily
draining partial or full-thickness wounds.
Use SilvaSorb Cavity for a seven-day antimicrobial barrier and where
control of heavy drainage or wound filling is desired.
SilvaSorb Site — for the invasive site of indwelling lines.
Use SilvaSorb Site for a seven-day antimicrobial barrier (and fluid
control) around the penetration sites for central lines, I.V. sites and
protruding orthopedic appliances.
SilvaSorb Gel — for wounds with dry to moderate exudate.
Use SilvaSorb Gel for a three-day antimicrobial barrier, plus the
moisture donating benefits of hydrogel.
Although silver has long been known as an antimicrobial, it
had two inherent weaknesses; it is inactivated quickly and
is cytotoxic in high concentrations.
Several years ago Medline overcame these limitations when we
introduced Arglaes, and then SilvaSorb, to the medical community.
These were the first dressings to harness the power of controlledrelease
ionic silver as an effective antimicrobial.
With these dressings, it became possible to control bioburden at
the wound site for several days, without harming healthy tissue
and without the use of antibiotics.
Medline pioneered the use of controlled-release silver dressings.
Not too much. Not too little.
SilvaSorb controls bioburden without harming healthy tissue.
Silver ions have long been recognized for their broad
spectrum antimicrobial action. Overwhelming evidence has
shown that concentrations well below a part per million are
effective against the microorganisms commonly encountered
in the clinical setting. However, too much silver can be
harmful to the tissue cells in an open wound bed.
SilvaSorb uses a combination of MicroLattice polymer and
stabilized silver technologies to produce a controlled-release
silver, antimicrobial wound dressing with moisture
management. SilvaSorb maintains a level of ionic silver that is
sufficient to control microorganisms without harming
healthy tissue cells.This precision release mechanism is active
against a broad spectrum of microbes including MRSA,
VRE, E.coli and Pseudomonas, as well as fungi and yeasts.
Other silver dressings that lack the control over the release of
silver may cause staining of surrounding tissues (see Figure 1)
or lead to cytotoxicity of tissue cells typically found in the
wound bed (see Figure 2).These cells are critical to the
wound healing process such as proliferation, angiogenesis and
matrix protein deposition. SilvaSorb overcomes this
limitation by controlling the level of antimicrobial ionic
silver at 11⁄2 ppm throughout the wear time of the dressing.
SilvaSorb offers a broad spectrum antimicrobial without
staining, discoloration or cytotoxicity of tissue cells.
Figure 1. The photos above show SilvaSorb, Acticoat 7
and Silver Nitrate applied beneath a transparent film.
The second photo shows the staining left behind after
the dressings are removed.
With the dressings on
With the dressings removed
SilvaSorb does not stain the skin, making
it easier to observe wound conditions.
SilvaSorb Acticoat 7 Silver Nitrate
SilvaSorb Acticoat 7 Silver Nitrate
Large doses of silver can harm new cell growth.1
When fibroblasts and keratinocytes are exposed to high levels of
silver, such as those in Acticoat, there are large zones devoid of
proliferating cells (shown by white areas in the images above).
A = Low level silver (SilvaSorb)
B = High level silver (metal-coated Acticoat)
Detection of all Cells
bright field microscopy
Control
(no silver)
SilvaSorb
(targeted
silver)
Acticoat
(high level
silver)
Fibroblast Viability and Cytotoxicity Study
Too much silver can harm healthy tissue.The photographs below show that Acticoat® kills healthy
tissue cells while SilvaSorb does not.
Viable Cells (Green)
fluorescence microscopy
with green filter
Non-Viable Cells (red)
fluorescence microscopy
with red filter
Dressing
Figure 2. The viability of tissue fibroblasts is not
apparent when cells are viewed under normal microscopic
conditions.Vital dyes distinguish cell viability by
staining living cells green and dead cells red under
fluorescent microscopy.
An identical field of tissue culture cells was exposed to
either a control matrix, SilvaSorb or Acticoat. Panels to
the left under normal bright field conditions allow
observations of all features. the middle panel, under a
green filter, shows only living cells. Panels to the right
under a red filter, show only dead cells.
Dressing Dressing
Dressing Dressing Dressing
Dressing
Dressing
Dressing
Dressing
SilvaSorb is a fast-acting, long lasting
antimicrobial
Figure 4. SilvaSorb is fast-acting.1
Figure 3. SilvaSorb provides an
antimicrobial barrier for up to seven days.4
SilvaSorb harnesses the power of ionic
silver, releasing silver at a controlled
level for broad spectrum antimicrobial
action, without harming tissue cells.
The ionic silver is suspended in the
SilvaSorb dressing to control its
release over a period of up to seven
days. It offers antimicrobial protection
over a broad spectrum of bacteria and
fungi, including MRSA and VRE
(see Figures 3, 4 and 5).
SilvaSorb kills the microbes that are
absorbed into the dressing through
wound exudate, but is completely
biocompatible with the tissue cells
of healing.
Zone of Inhibition (diameter in mm)
Acticoat
Culture Strains SilvaSorb Absorbent Control
Escherichia coli (ToP 10F) 13 12 0
Escherichia coli (8739) 11 10 0
Klebseilla pneumoniae (33472) 10 9 0
Klebseilla pneumoniae (33475) 10 9 0
Staphylococcus aureus (25923) 13 11 0
Staphylococcus aureus (MRSA) 12 10 0
Staphylococcus aureus 13 10 0
Staphylococcus aureus (coag neg) 14 13 0
Pseudomonas aeruginosa (27853) 14 11 0
Pseudomonas aeruginosa (9027) 12 10 0
Proteus mirabilis 9 5 0
Bacillus subtilis (Endospore former) 11 9 0
Streptococcus (Group A) 16 11 0
Enterbacter cloacae 9 8 0
Enterococcus faecalis (29212) 12 9 0
Enterococcus faecium (VRE) 15 12 0
Enterococcus faecium 13 10 0
Serratia marcescens 11 10 0
Listeria monocytogenes (10403) 16 14 0
Candida parapsilosis 12 13 0
Candida albicans 13 12 0
Candida albicans (10231) 11 11 0
Aspergillus niger (16404) 15 14 0
Acinetobacter baumanii (15149) 12 ND ND
Acinetobacter baumanii (15308) 13 ND ND
Figure 5. MRSA is a notorious strain of Staphylococcus aureus (left plate in panel)
that is resistant to penicillin (a) and Methicillin (c), but remains sensitive to Vancomycin
(e). Clearing zones around the test samples show that the culture is susceptible.
Methicillin resistance is a genetic trait that bears no relationship to sensitivity to the
broad spectrum antimicrobial action of silver. In this case, both Staph. aureus and MRSA
are equally sensitive to the silver in SilvaSorb (b) and Acticoat (d).1
Table 1. SilvaSorb protects against a broad spectrum of bacteria and fungi.1
The MicroLattice® in SilvaSorb controls the release of silver.
The controlled-release ionic silver provides a barrier against
infection for up to seven days.
The dressing can absorb
more than five times its
weight in exudate.
Ionic silver is suspended in SilvaSorb’s
MicroLattice until moisture from the
wound triggers its release.
Is there any evidence of silver-resistant bacteria?
Silver is an effective broad spectrum antimicrobial.
But will increased use result in widespread
resistance as we have seen with other antimicrobial
agents used in the clinical setting?
Microbes are everywhere so of course there are
some that can live in the presence of silver.They
are resistant to ionic silver. However, only a few of
the several million different organisms that have
been cataloged are medically important.The
antimicrobial properties of silver have been known
for over 3,000 years and so far, resistance has not
been associated with its use.
The reason is that, unlike antibiotics, silver has
multiple targets when it attacks bacteria. So even if
an organism mutated and developed a resistance to
one of those targets, the remaining targets would
still be susceptible.10 Clinical data suggests that
“prolonged exposure to silver dressings does not
lead to silver resistant bacteria.”9
SilvaSorb is composed of a synthetic, polyacrylate
hydrophilic matrix that contributes to its flexibility,
elasticity and absorbency.
SilvaSorb’s unique architecture begins with its
MicroLattice matrix — the basic structure that allows
moisture to be absorbed and the ionic silver to be
released.
SilvaSorb’s unique stabilized silver is suspended as minute
particles throughout the molecular scaffolding of
MicroLattice for even distribution of ionic silver.
Exposure to wound moisture dissolves the silver reservoir
and stimulates the release of silver ions into the wound.
The amount of silver released is controlled by a
mechanism which not only regulates the release of silver,
but also prevents staining and discoloration by protecting
the silver ions from light energy.
As more fluid is absorbed over time, more silver ions are
released, creating a controlled-release antimicrobial effect.
In many ways, the MicroLattice acts like the body’s skin:
• It’s biocompatible
• It provides a barrier against infection
• It offers moisture management
• It’s comfortable
In addition to controlling bioburden, another key factor
in wound healing is managing moisture level.
SilvaSorb dressings are made of a special polymer that
absorbs more than five times its weight in fluid.That’s
not only more than all other silver dressings, it’s several
times more than calcium alginates or similar absorptive
products.
This allows SilvaSorb to be left in place for longer
periods of time compared to other wound dressings,
even on heavily draining wounds.
If the wound is dry, SilvaSorb can still help.The
dressings are 20% water, giving them the unique ability
to donate moisture when needed.
Advanced fluid management helps provide a moist
wound healing environment for the full spectrum of
wounds. SilvaSorb will not dry out a wound and it will
not macerate the surrounding skin.
Absorbs excess fluid and donates
moisture — SilvaSorb does both.
0
3
6
9
12
15
SilvaSorb
Cavity
Aquacel Kaltostat
Moisture Uptake (g)
2" x 2" sizes, after 8 hours
0
3
6
9
12
15
SilvaSorb Acticoat
Foam
Silverlon
Moisture Uptake (g)
2" x 2" sizes, after 8 hours
Acticoat
7
Acticoat
Absorbent
Figure 7. SilvaSorb Cavity absorbs several times more
fluid than other dressings designed for fluid management.1
Figure 6. SilvaSorb holds considerably more fluid
than other silver dressings.1
0
2
4
6
8
10
12
SilvaSorb
Aquacel Ag
1 2 3 4 5 6 7 8 24
2“ x 2”, Time (hours)
Moisture Absorption (g)
Figure 8. A comparison of the 24 hour absorbency of
saline by SilvaSorb and Aquacel Ag.1
® ® ® ® ®
® ® ®
Feature SilvaSorb® Gel SilvaSorb® Aquacel AG® Silvercel® Acticoat 7®
Effective antimicrobial yes yes yes yes yes
Highly absorbent no yes yes yes no
Moist yes yes no no no
Non-cytotoxic yes yes yes yes no
Transparent yes yes no no no
Self-activating yes yes yes yes no
Self regulating yes yes yes yes no
Does not stain yes yes yes yes no
Non-adherent yes yes no no no
Easy to apply yes yes yes yes yes
A Comparison of Broad Spectrum Antimicrobial Silver Dressings
SilvaSorb Gel – the first antimicrobial
silver hydrogel
SilvaSorb Gel combines a hydrogel’s ability to
maintain a moist wound healing environment
with the benefits of bioburden control.
SilvaSorb Gel’s unique architecture features
MicroLattice particles that suspend ionic silver
within its molecular “scaffolding,” continuously
releasing silver for up to three days.
Controlled release of antimicrobial silver ions
commences upon the gel’s exposure to the
wound. MicroLattice release technology is so
sensitive that even contact with a dry wound
bed or intact skin enables the release.The amount of silver released is controlled by a suppression mechanism
that not only regulates the release of silver, but also prevents skin staining and discoloration.
SilvaSorb is completely biocompatible. It’s non-irritating, non-sensitizing and will not harm new granulation
tissue.The inherent versatility of amorphous hydrogels makes SilvaSorb ideal for even difficult to dress
wounds like cavity wounds and burns.
“Topical antimicrobials, including silver sulfadiazine, Sulfamylon®, SilvaSorb and gentamicin sulfate, showed
superior bacterial inhibition and bactericidal properties in vitro, demonstrating complete inhibition of growth
in quantitative cultures at 24, 48 and 72 hours.”2
SilvaSorb Gel is available in small, unit-dose sizes
up to 16 oz. jars for broader applications (e.g. burns).
Selected SilvaSorb case studies
Pressure Ulcer
A 93 year-old wheelchair-bound male with no significant
nutritional deficits developed a chronic trochanteric pressure
ulcer.The ulcer was treated with various wound care therapies for
four months without progress.The wound bed was friable and
therefore presumptive for high bioburden, it was elected to start
an antimicrobial dressing in conjunction with off-loading the
affected hip. Closure was attained within four weeks.
Source: Mary Nametka, RN, MSN, CS, CWS, CWCN,Adventist Medical Center,
Portland OR, Study Site Avamere LTC Facility, Portland OR. Presented at the Annual
Symposium on Advanced Wound Care,April 27-29, 2002
Venous Leg Ulcer
MC, a 94 year-old female, presented with severe pain in a VLU
on the right LE that had been open for more than 12 weeks.The
patient was treated by mild compression in combination with
SilvaSorb to modulate pain and control bioburden. MC was well
tolerant of the treatment and the wound closed in eight weeks.
Source: Mary Nametka, RN, MSN, CS, CWS,WCN and Bruce L. Gibbins PhD,
CTO, Associates in Wound Care, Kenosha,WI and Department of R&D, AcryMed,
Portland, OR. presented at the Symposium on Advanced Wound Care, May 1-2, 2001.
Time period: 4 weeks
Time period: 8 weeks
Key clinical study results: 1) the use of SilvaSorb increases the incidence of successful graft closure.4,
2) a retrospective study showed that 81% of venous leg ulcers healed in 8-10 weeks. Patients reported decreased
pain.7, 3) SilvaSorb use in wounds of mixed etiologies led to the prevention of infection and reduction in
dressing change frequency.3
SilvaSorb is a dynamic dressing that can be used in a wide variety of settings.What follows is a summary of
several case studies that demonstrate SilvaSorb’s wide range of applications.
Contaminated Surgical Wound
83 year-old male with a history of diabetes and arterial insufficiency.
Surgical wound had been treated with gauze and saline,multilayered
polyacrylate dressing pad.Wound cultured positive for
proteus and staph aureus with 100% slough.Treatment: Silver gel
for 2 weeks, changed to silver cavity for 4 weeks.Wound closed
at 6 weeks.
Ruth Tamulonis, RN, MS,CWOCN, Marijke Carson, PT, CMLDT, Kathi Petersen,
RN, CCRN, Marshalltown Medical & Surgical Center, Marshalltown, IA and Carol
Paustian, RN, BSN,CWOCN, Omaha, NE
Time period: 8 weeks
Sacral Pressure Ulcer
A female patient in her 40s with immobility due to Multiple
Sclerosis. A sacral pressure ulcer was identified on 9/1/01; this
area had been open most of the previous two years. Nutritional
level was suboptimal with a weight of 113 pounds.The pressure
area evolved to a Stage IV with connective tissue visible in the
base without evidence of granulation. SilvaSorb was chosen due
to the frequent contamination of the area from fecal incontinence
and history of sepsis related to UTIs. Over a period of eight
weeks the wound completely closed with the patient successfully
resuming activities outside of her room.
Source: Mary Nametka, RN, MSN, CS, CWS, CWCN,Adventist Medical Center,
Portland OR, Study Site Avamere LTC Facility, Portland OR. Presented at the Annual
Symposium on Advanced Wound Care,April 27-29, 2002
Lymphedema
This 42-year-old morbidly obese woman presented with severe
lymphedema and a chronic superficial open area of the left leg.
Wound drainage was reported as malodorous and copious, requiring
dressing changes 2-3 times per day.The patient complained that
her carpet and furnishings were becoming soiled with the poorly
contained drainage. SilvaSorb was selected for management of the
heavy exudate and for odor control.The dressing was able to
contain the exudate with a daily dressing change and the patient
stated that odor was no longer a problem.The weepy areas
resolved over a period of approximately eight weeks.
Source: Mary Nametka, RN, MSN, CS, CWS,WCN, Associate in Wound Care,
Kenosha,WI. Presented at WOCN 33rd Annual Conference, June 2-6, 2001
Time period: 8 weeks
Time period: 8 weeks
Oncology
A 59 year-old female with metastatic breast cancer and a nonhealing
surgical site L chest wall wound. On initial exam the
patient complained of severe pain on dressing change and of a
large amount of malodorous drainage which required
replacement of dressing 2-3 times per day.The use of the Silver
Polymer Dressing resulted in decreased frequency of dressing
change to once every 48 h with elimination of odor and report
of reduced pain both during wear and on removal.
Source: Mary Nametka, RN, MSN, CS, CWS,WCN, Associate in Wound Care,
Kenosha,WI. Presented at WOCN 33rd Annual Conference, June 2-6, 2001
Venous Leg Ulcer
A 77 year-old male with a 25 year history of venous insufficiency
and a VLU on the right lower extremity that was not responsive
to 1/2 years of treatment by compression alone. Silver polyacrylate
was substituted for the rayon contact layer under continuation of
multi-layer compression. Closure of the wound was achieved
in 3 weeks.
Source: Mary Nametka, RN, MSN, CS, CWS,WCN, and Bruce L. Gibbins PhD,
CTO, Associate in Wound Care, Kenosha,WI. and Department of R & D, AcryMed,
Portland, OR, Presented at the Symposium on Advanced Wound Care, May 1-2, 2001
Time period: 3 weeks
Selected SilvaSorb case studies
(continued)
Laceration
A 78 year-old female fell at home and suffered a laceration to the
left lower extremity. She was treated with traditional topical
dressings and IV antibiotics and discharged to home with an open
wound. She presented to our clinic with a full thickness wound
measuring 4.9 x 2.8 x 1.5 cms with undermining from 6:00 to
10:00 for up to 2 cms and a moderate amount of drainage. Silver
MicroLattice was used as the primary dressing.The wound was
completely closed in 108 days.
Oscar J. Paz-Altschul,MD, FACS, Maeve Curran, PT, Joy Richardson, RD, CDE, Katie
Esqueda PTA; Desert Regional Medical Center, Palm Springs, CA, Presented at the
Symposium on Advanced Wound Care, April 28 - May 1, 2003
Time period: 11 weeks
Time period: 12 weeks
Venous Leg Ulcer
The patient is a 60 year old female with a long history of
NIDDM with foot ulcers resulting in a left BKA.The patient was
well nourished and her blood sugars were stable throughout this
home care course.The harvest sites, on the right lower extremity
were full thickness dehisced surgical wounds. Silver ion therapy
was initiated because of the dressing’s antimicrobial properties as
well as its fluid handling capabilities. At the start of silver ion
therapy, the wound measured 6.5 cm x 2.3 cm x 0.2 cm with
approximately 95% viable granular tissue and 5% slough.The
wound continued to progress until closure at 12 weeks of silver
ion therapy.
Source: Susan B. Rose, RN, BSN,CWOCN and Lori Maguire, RN, of Gentiva
Health Services,Tucson,AZ. Joyce J. Norman, RN, BSN,CWOCN, and Margaret
Falconio-West, RN,APN, BSN, CGRN,CWOCN, Mundelein, IL. Presented at the
Clinical Symposium on Advances in Skin and Wound Care,April 28-May 1, 2003
Time period: 12 weeks
Contaminated Stage IV Pressure Ulcer
43 year old, paraplegic female who suffered a traumatic injury
secondary to a motor vehicle accident in 1998. She was admitted
with a stage IV pressure ulcer over the right greater trochanter.
The wound measured 5.8 x 7.5 x 2.0 cm and was covered with
70% slough with two protruding muscle bellies.The wound had
a moderate amount of foul smelling, thick, purulent exudate.An
antimicrobial silver hydrogel was used and after approximately
one month, the wound measured 3.9 x 4.5 x 1.2 and the drainage
had reduced significantly. Odor was eliminated almost immediately.
The two muscle bellies had contracted.The wound continues to
progress, slough was autolytically debrided, and the wound bed
is 100% granulating with only mild periwound erythema.
Salome Agbim, ND CNS APRN BC and Kimberly Miner, ND CNS CWCN,
Wound Care Associates, Englewood, Colorado. Presented at the Clinical Symposium on
Advances in Skin and Wound Care, September 30-October 1, 2004.
Contaminated Surgical Wound
The wound was covered with 80% slough and 20% granulation
tissue.There was an 88% reduction in wound size with silver
containing gel for two weeks. At that point, he was lost to follow up.
Ruth Tamulonis, RN, MS,CWOCN, Marijke Carson, PT, CMLDT, Kathi Petersen,
RN, CCRN, Marshalltown Medical & Surgical Center, Marshalltown, IA and Carol
Paustian, RN, BSN,CWOCN, Omaha, NE. Presented at the Clinical Symposium
on Advances in Skin and Wound Care,April 28-May 1, 2003
Time period: 1 week
Burn Patient
In patients with less than 20% TBSA, partial thickness burns,
one of the most common treatments is the application of silver
sulfadiazine (SSD) wrapped with a gauze dressing which is
changed BID. Instead of SSD, a new antimicrobial gel that slowly
releases silver into the wound was used. It is covered with dry
sterile dressing of choice. The hydrogel base provides a moist
environment for up to three days, while allowing visualization
of the wound. Silver ions are released slowly, so that the burn
receives a constant stream of silver, thus eliminating the bolus
effect.The gel is easy to apply and remove, which increases
compliance while reducing pain associated with dressing changes.
Conclusion:The new procedure demonstrated improved healing
rates, decreased pain, increased compliance, earlier discharge, and
overall cost effective burn treatment.
Dr. Jimmy Giddens, Co-Director of Hillcrest Medical Center, Alexander Burn Unit,
Tulsa, OK. Presented at the American Burn Association Meeting, March 23-27, 2004,
Vancouver, BC.
Time period: 3 weeks
SilvaSorb Sheets
for shallow wounds with light to moderate exudate:
• Can be easily cut to fit any size or shape
of wound
• Absorbs up to five
times its weight in
exudate
• Controls bioburden
up to seven days
• Donates moisture to
dry wound beds
• Self-activating
• Will not stain
surrounding skin
Five SilvaSorb dressing styles cover
a wide variety of settings
SilvaSorb Gel
for wounds with no to light exudate:
• Controls bioburden up to three days
• Donates moisture to dry wound beds
• Self-activating
• Will not stain
surrounding skin
• Easy to apply
and remove
SilvaSorb Perforated Sheets
for flat wounds with moderate to heavy exudate:
• Can be easily cut to fit any size or shape
of wound
• Absorbs up to five times
its weight in exudate
• Controls bioburden up
to seven days
• Donates moisture to
dry wound beds
• Self-activating
• Will not stain
surrounding skin
SilvaSorb Cavity
for cavity wounds with all exudate levels:
• Absorbs up to five times its weight in exudate
• Controls bioburden up to
seven days
• Donates moisture to dry
wound beds
• Self-activating
• Will not stain surrounding skin
SilvaSorb Site
for the invasive site of indwelling lines:
• Designed to wrap snugly around vascular and
non-vascular percutaneous devices such as IV
catheters, central venous lines, arterial
catheters, etc.
• Should be covered and secured with a
transparent film (e.g. Suresite®Window)
• Controls bioburden
up to seven days
• Donates moisture to
dry wound beds
• Self-activating
• Will not stain
surrounding skin
SilvaSorb Ordering Information
Item No. Description HCPCS Packaging
MSC9322EP Sheet, 2" x 2" A6242 5/bx, 5 bx/cs
MSC9344EP Sheet, 41⁄4" x 41⁄4" A6243 5/bx,5 bx/cs
MSC9348EP Sheet, 4" x 8" A6243 5/bx, 5 bx/cs
MSC9340EP Perforated Sheet, 41⁄4" x 41⁄4" A6243 5/bx, 5 bx/cs
MSC93410EP Perforated Sheet, 4" x 10" A6243 5/bx, 5 bx/cs
MSC9360EP Cavity, 6 gram none 5/bx, 5 bx/cs
MSC93025 Gel, .25 oz tube A6248 25/bx
MSC9301EP Gel, 1.5 oz tube A6248 12/cs
MSC9303 Gel, 3 oz tube pending 12/cs
MSC9308 Gel, 8 oz tube A6248 6/cs
MSC9316 Gel, 16 oz net wt. jar A6248 8/cs
MSC9310EP Site, 1" circular with slit A6242 30/cs
MSC9320EP Site, 13⁄4" circular with slit A6242 30/cs
Indications
• Pressure ulcers (Stage I-IV)
• Partial and full thickness wounds
• Leg ulcers
• Diabetic foot ulcers
• Grafted wounds and donor sites
• Skin tears
• Surgical wounds
• Lacerations and abrasions
• 1st and 2nd degree burns
Change Frequency
• May be left in place for up to 7 days.
Gel up to 3 days.
• Dressing change frequency will
depend upon the amount of exudate.
• Change the dressing if the exudate
begins to pool within the wound or
with significant strike-through on the
secondary dressing.
Contraindications
• Individuals with a known sensitivity
to silver.
Evidence Base References:
1. Data on file 2. Castellano JJ, Shafil SM, Ko F, Donate G,Wright TE, Mannari RJ, Payne WG, Smith DJ, Robson MC. Comparative evaluation of silver
containing antimicrobial dressings and drugs. Int Wound Journal. 4: 114-122. 3. Nametka M. Silver antimicrobial hydrophilic dressing benefits management
of recurrent non-healing wounds. Symposium on Advanced Wound Care. Baltimore. 2002. 4. Nametka M.A hydrophilic silver antimicrobial wound
dressing for site preparation and maintenance of human skin equivalent grafts to venous leg ulcers:Technical and clinical considerations. Clinical Symposium
on Advances in Skin & Wound Care, Nashville. 2000. 5. Nametka M. Silver antimicrobial absorbent wound dressing can contribute to cost control in
home care.Annual Clinical Symposium on Advances in Skin and Wound Care. Dallas. 2002. 6. Copty T, Glat P. Comparison of SilvaSorb Gel and silver
sulfadiazine on pediatric burn patients. Internal report on file. 7. Nametka M.Antimicrobial silver polymer contact layer for treatment of venous leg ulcers.
Symposium on Advanced Wound Care. Las Vegas. 2001. 8. Gibbons BL, Nametka M, Hopman LD. Pre-clinical and clinical evaluation of a new silver
antimicrobial chronic wound dressing. Symposium on Advanced Wound Care. Dallas. 2000.
As wound care changes,
Medline leads the way
From SilvaSorb to TenderWet Active, Medline
continues a legacy of breaking new ground. Our
products not only help improve outcomes, but
help reduce nursing time and lower costs.
Ask your Medline representative about our catalog
of advanced wound care products, or call us at
1-800-MEDLINE
1-800-MEDLINE | www.medline.com
©2008 Medline Industries, Inc.
Medline is a registered trademark of Medline Industries, Inc., SilvaSorb and MicroLattice are registered trademarks of AcryMed, Inc., Aquacel Ag and Kaltostat are
registered trademarks of E.R. Squibb & Sons, LLC, Silverlon is a registered trademark of Bartholomew A. Flick, Arglaes is a registered trademark of Unomedical,
Acticoat is a trademark of T.J. Smith & Nephew Limited Corporation, Silvercel is a registered trademark of Johnson & Johnson Corporation, Sulfamylon is a
registered trademark of Mylan Bertek Pharmaceuticals Inc.
MKT207329 / LIT111 / 3ZPN / 20M |
|